152 related articles for article (PubMed ID: 38336732)
1. Prostate cancer presentation and management in the Middle East.
Sayan M; Langoe A; Aynaci O; Eren AA; Eren MF; Kazaz IO; Ibrahim Z; Al-Akelie OT; Al-Mansouri L; Abu-Hijlih R; Moningi S; Abou Chawareb E; El Hajj A; Orio PF; Mula-Hussain L
BMC Urol; 2024 Feb; 24(1):35. PubMed ID: 38336732
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
[TBL] [Abstract][Full Text] [Related]
3. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic characteristics of lethal prostate cancer.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
[TBL] [Abstract][Full Text] [Related]
5. Stage shift in PSA-detected prostate cancers - effect modification by Gleason score.
Pashayan N; Pharoah P; Neal DE; Hamdy F; Donovan J; Martin RM; Greenberg D; Duffy SW
J Med Screen; 2009; 16(2):98-101. PubMed ID: 19564523
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening.
Leung AK; Hugar L; Patil D; Wong L; Carthon B; Carney KJ; Birdsong G; Moses KA; Master VA
Urology; 2018 Jul; 117():101-107. PubMed ID: 29656066
[TBL] [Abstract][Full Text] [Related]
7. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
8. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
9. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
Fowler JE; Bigler SA
Cancer; 1999 Sep; 86(5):836-41. PubMed ID: 10463983
[TBL] [Abstract][Full Text] [Related]
11. Prognostic features in men who died of prostate cancer.
Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
13. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community.
Ugwumba FO; Nnabugwu II
Ann Afr Med; 2022; 21(2):153-157. PubMed ID: 35848648
[TBL] [Abstract][Full Text] [Related]
15. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
16. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
Beyer DC; Thomas T; Hilbe J; Swenson V
Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
[TBL] [Abstract][Full Text] [Related]
17. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
18. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.
Eastham JA; Kattan MW; Fearn P; Fisher G; Berney DM; Oliver T; Foster CS; Møller H; Reuter V; Cuzick J; Scardino P;
Eur Urol; 2008 Feb; 53(2):347-54. PubMed ID: 17544572
[TBL] [Abstract][Full Text] [Related]
19. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
Feneley MR; Gillatt DA; Hehir M; Kirby RS
Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
